Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00646191
- Testing
- adalimumab
- Volunteers
- 137 people
- Sponsor
- Abbott
Psoriasis
Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
efficacy study in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206387
- Testing
- Desoximetasone Spray 0.25%
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Psoriasis
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT07130604
- Testing
- D-2570
- Where
- China
- Volunteers
- 390 people
- Sponsor
- InventisBio Co., Ltd
Moderate to Severe Plaque Psoriasis
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive KHK4827 or placebo for 12 weeks
- Trial name
- NCT02982005
- Testing
- KHK4827
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
- Trial name
- NCT03897075
- Testing
- Tildrakizumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 99 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03219437
- Testing
- risankizumab, methotrexate
- Where
- 11 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- AbbVie
Psoriasis
A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. After single asending dose and mutiple asending dose in health subjects.
- Trial name
- NCT04839328
- Testing
- 60mg Hemay005
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT00237887
- Testing
- adalimumab
- Volunteers
- 1,212 people
- Sponsor
- Abbott
Psoriasis
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
- Trial name
- NCT02387801
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
- Trial name
- NCT02412644
- Testing
- apremilast
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Arthritis, Psoriatic
MYL-1401A Efficacy and Safety Comparability Study to Humira®
To assess the equivalence of MYL-1401A to Humira® with regards to efficacy in subjects with moderate-to-severe chronic plaque psoriasis
- Trial name
- NCT02714322
- Testing
- MYL-1401A (Adalimumab), Humira® (Adalimumab)
- Where
- 33 sites in Bulgaria, Estonia and 4 more
- Volunteers
- 294 people
- Sponsor
- Mylan Inc.
Plaque Psoriasis
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT02899988
- Testing
- Mirikizumab
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 205 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Overweight or Obesity
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1…
- Trial name
- NCT06857942
- Testing
- Tirzepatide
- Where
- 38 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis
This is a multicenter, Phase 2, double-blind, placebo-controlled study in subjects with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response or are intolerant to conventional disease-modifying…
- Trial name
- EQUATOR (NCT03101670)
- Testing
- filgotinib
- Where
- 25 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 131 people
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
- Trial name
- NCT02407041
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Galectin Therapeutics Inc.
Active Plaque Psoriasis
Study to Assess VB-201 in Patients With Psoriasis
The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.
- Trial name
- NCT01001468
- Testing
- VB-201
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis
The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.
- Trial name
- NCT03924427
- Testing
- BMS-986165
- Where
- 27 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03210259
- Testing
- Humira®, BI 695501
- Where
- 49 sites in United States, Germany and 5 more
- Volunteers
- 259 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis (PPP)
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles.
- Trial name
- NCT04451720
- Testing
- Risankizumab
- Where
- 39 sites in Japan
- Volunteers
- 119 people
- Sponsor
- AbbVie